Previous 10 | Next 10 |
The following medical companies have filed for mixed shelf offerings: More news on: Ardelyx, Inc., Vaxart, Inc., Alpine Immune Sciences, Inc., Healthcare stocks news, , Read more ...
Marathon Patent Group (NASDAQ: MARA ) -14% . More news on: Marathon Patent Group, Inc., Fuwei Films (Holdings) Co., Ltd., Urban One, Inc., Stocks on the move, , Read more ...
- ALPN-202 is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today annou...
Evoke Pharma (NASDAQ: EVOK ) +85% on FDA approval . More news on: Evoke Pharma, Inc., Theratechnologies Inc., Broadway Financial Corporation, Stocks on the move, , Read more ...
Broadway Financial (NASDAQ: BYFC ) +129% . More news on: Broadway Financial Corporation, Urban One, Inc., Cohen & Company Inc., Stocks on the move, Read more ...
Gainers: Alpine Immune Sciences (NASDAQ: ALPN ) +174% . More news on: Alpine Immune Sciences, Inc., Aethlon Medical, Inc., Urban One, Inc., Stocks on the move, , Read more ...
Let me ask you a question: Why would anyone buy penny stocks ? Is it because they saw the Wolf of Wall Street or Boiler Room and want to feel a rush of adrenaline? Maybe they saw the movie Wall Street and just want to feel like Bud Fox for a day. All kidding aside though, there’s some tr...
Alpine Immune Sciences (NASDAQ: ALPN ) enters into an exclusive global option and license agreement with AbbVie (NYSE: ABBV ) for lead candidate ALPN-101. More news on: Alpine Immune Sciences, Inc., AbbVie Inc., Healthcare stocks news, Read more ...
- Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie’s commitment to developing novel therapies in Immunology - Alpine Immune Sciences to receive $60...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the AACR Virtual Annual Meeting II, taking place June...
News, Short Squeeze, Breakout and More Instantly...
Alpine Immune Sciences Inc. Company Name:
ALPN Stock Symbol:
NASDAQ Market:
Alpine Immune Sciences Inc. Website:
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades...
2024-05-19 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceutic...